Serum sarcosine is a risk factor for progression and survival in patients with metastatic castration-resistant prostate cancer

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

References

• 1  Siegel R, Naishadham D, Jemal A. Cancer statistics 2013. CA Cancer J. Clin.63(1),11–30 (2013).
  MedlineGoogle Scholar
• 2  Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urologic Clin. North Am.28(3),555–565 (2001).
  Medline CASGoogle Scholar
• 3  Tannock IF, De Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med.351(15),1502–1512 (2004).
  Medline CASGoogle Scholar
• 4  Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med.351(15),1513–1520 (2004).▪▪ References [3,4] represent the two landmark studies that demonstrated a survival benefit for metastatic castration-resistant prostate cancer patients receiving docetaxel-based chemotherapy.
  Medline CASGoogle Scholar
• 5  Armstrong AJ, Eisenberger MA, Halabi S et al. Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. Eur. Urol.61(3),549–559 (2012).
  Medline CASGoogle Scholar
• 6  Sreekumar A, Poisson LM, Rajendiran TM et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature457(7231),910–914 (2009).▪▪ Demonstrates for the first time that metabolomic profiles delineate a potential role for sarcosine in prostate cancer progression.
  Medline CASGoogle Scholar
• 7  Jentzmik F, Stephan C, Miller K et al. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. Eur. Urol.58(1),12–18; discussion 20–11 (2010).
  Medline CASGoogle Scholar
• 8  Wu H, Liu T, Ma C et al. GC/MS-based metabolomic approach to validate the role of urinary sarcosine and target biomarkers for human prostate cancer by microwave-assisted derivatization. Anal. Bioanal. Chem.401(2),635–646 (2011).
  Medline CASGoogle Scholar
• 9  Cao DL, Ye DW, Zhu Y, Zhang HL, Wang YX, Yao XD. Efforts to resolve the contradictions in early diagnosis of prostate cancer: a comparison of different algorithms of sarcosine in urine. Prostate Cancer Prostatic Dis.14(2),166–172 (2011).
  Medline CASGoogle Scholar
• 10  Struys EA, Heijboer AC, van Moorselaar J, Jakobs C, Blankenstein MA. Serum sarcosine is not a marker for prostate cancer. Ann. Clin. Biochem.47(Pt 3),282 (2010).
  MedlineGoogle Scholar
• 11  Sreekumar A, Poisson LM, Rajendiran TM et al. Re: Florian Jentzmik, Carsten Stephan, Kurt Miller, et al. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. Eur. Urol.58(3),e29–e30 ; author reply e31–e32 (2010).
  MedlineGoogle Scholar
• 12  Colleselli D, Stenzl A, Schwentner C. Re: Florian Jentzmik, Carsten Stephan, Kurt Miller, et al. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. Eur. Urol.58(5),e29–e30 (2010).
  MedlineGoogle Scholar
• 13  Lucarelli G, Fanelli M, Larocca AM et al. Serum sarcosine increases the accuracy of prostate cancer detection in patients with total serum PSA less than 4.0 ng/ml. Prostate72(15),1611–1621 (2012).▪ Provides evidence that serum sarcosine has a higher predictive value than PSA for prostate cancer detection in patients with PSA <4 g/ml. Moreover, in this subset of patients, the percentage of low-/intermediate-grade cancers was positively associated with sarcosine levels.
  Medline CASGoogle Scholar
• 14  Miyake M, Gomes Giacoia E, Aguilar Palacios D, Rosser CJ. Sarcosine, a biomarker for prostate cancer: ready for prime time? Biomark. Med.6(4),513–514 (2012).
  Google Scholar
• 15  Ackerstaff E, Glunde K, Bhujwalla ZM. Choline phospholipid metabolism: a target in cancer cells? J. Cell. Biochem.90(3),525–533 (2003).
  Medline CASGoogle Scholar
• 16  Cheng LL, Wu C, Smith MR, Gonzalez RG. Non-destructive quantitation of spermine in human prostate tissue samples using HRMAS ¹H NMR spectroscopy at 9.4 T. FEBS Lett.494(1–2),112–116 (2001).
  Medline CASGoogle Scholar
• 17  Swanson MG, Zektzer AS, Tabatabai ZL et al. Quantitative analysis of prostate metabolites using ¹H HR-MAS spectroscopy. Magn. Reson. Med.55(6),1257–1264 (2006).
  Medline CASGoogle Scholar
• 18  Trock BJ. Application of metabolomics to prostate cancer. Urol. Oncol.29(5),572–581 (2011).
  Medline CASGoogle Scholar
• 19  Song YH, Shiota M, Kuroiwa K, Naito S, Oda Y. The important role of glycine N-methyltransferase in the carcinogenesis and progression of prostate cancer. Mod. Pathol.24(9),1272–1280 (2011).
  Medline CASGoogle Scholar
• 20  Stabler S, Koyama T, Zhao Z et al. Serum methionine metabolites are risk factors for metastatic prostate cancer progression. PLoS One6(8),e22486 (2011).
  Medline CASGoogle Scholar
• 21  Montrose DC, Zhou XK, Kopelovich L et al. Metabolic profiling, a noninvasive approach for the detection of experimental colorectal neoplasia. Cancer Prev. Res. (Phila.)5(12),1358–1367 (2012).▪ Describes the metabolomic landscape of colorectal tumors and demonstrates that sarcosine and 2-hydroxyglutarate levels are significantly elevated in this cancer.
  Medline CASGoogle Scholar
• 22  Armstrong AJ, Garrett-Mayer E, Ou Yang YC et al. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J. Clin. Oncol.25(25),3965–3970 (2007).
  MedlineGoogle Scholar
• 23  Halabi S, Vogelzang NJ, Kornblith AB et al. Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. J. Clin. Oncol.26(15),2544–2549 (2008).
  MedlineGoogle Scholar
• 24  Armstrong A, Garrett-Mayer ES, Yang OY et al. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX 327 study analysis. Clin. Cancer Res.13(21),6396–6403 (2007).
  Medline CASGoogle Scholar
• 25  Gu H, Gowda GN, Raftery D. Metabolic profiling: are we en route to better diagnostic tests for cancer? Future Oncol.8(10),1207–1210 (2012).
  CASGoogle Scholar